GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation

뉴스 본문을 불러오고 있어요.

GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation | 웨이프 WAPE

GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation

기사 요약

관련 종목

댓글 —